Efficacy and tolerability of olanzapine in elderly patients with psychotic disorders: A prospective study

Annals of Clinical Psychiatry

Volumn 12, Issue 1, 2000, Pages 11-18

  Madhusoodanan, Subramoniam ^a   Brenner, Ronald ^a   Suresh, Padma ^b   Concepcion, Nancy M ^c   Florita, Cesar D ^d   Menon, Geetha ^e   Kaur, Amarjit ^e   Nunez, Giovanny ^b   Reddy, Harsha ^a  

^a ST JOHN S EPISCOPAL HOSPITAL   (United States)

^b CABRINI MEDICAL CENTER   (United States)

^c SUNY DOWNSTATE MEDICAL CENTER   (United States)

^d LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^e ST VINCENT S HOSPITAL   (United States)

Author keywords

Efficacy; Elderly; Olanzapine; Psychotic; Tolerability

Indexed keywords

AMANTADINE; BENZATROPINE MESILATE; CARBAMAZEPINE; LITHIUM CARBONATE; LORAZEPAM; OLANZAPINE; PROLACTIN; VALPROATE SEMISODIUM;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GERONTOPSYCHIATRY; HUMAN; LABORATORY TEST; MALE; NEGATIVE SYNDROME; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; PSYCHOSIS; RASH; RATING SCALE; SCHIZOIDISM; SCHIZOPHRENIA; VERTIGO; WEIGHT GAIN;

AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DRUG INTERACTIONS; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PIRENZEPINE; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; TREATMENT OUTCOME;

EID: 0034007772     PISSN: 10401237     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1009018809174     Document Type: Article

References (23)

1. Jeste DV, Caligiuri MP, Paulsen JS, et al.: Risk of tardive dyskinesia in older patients; a prospective longitudinal study of 266 outpatients. Arch Gen Psychiatry 1995; 52:756-765
2. Salz BL, Kane JM, Woerner MG, et al.: Prospective study of tardive dyskinesia in the elderly. Psychopharmocol Bull 1989; 25:52-56
3. Avorn J, Manane M, Everitt DE, et al.: Clinical assessments of extrapyramidal signs in nursing home patients given antipsychotic medications. Arch Intern Med 1994; 154:1113-1117
4. Bymaster FP. In vitro and in vivo biochemistry of olanzapine. J Clin Psychiatry Monograph 1997; 15(2):10-12
5. Baldwin DS, Montgomery SA: First clinical experience with olanzapine (LY170053): Results of an open-label and safety and dose-ranging study in patients with schizophrenia. Int Clin Psychopharmacol 1995; 10:239-244
6. Tollefson GD, Beasley CM, Tran PV, et al.: Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective disorders: Results of an international collaborative. Am J Psychiatry 1997; 154:4
7. Beasley CM, Efficacy of olanzapine: An overview of pivotal clinical trials. J Clin Psychiatry Monograph 1997; 15(2):16-18
8. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bull 1987; 13:261-276
9. Guy W, ed.: ECDEU Assessment Manual for Psychopharmacology. Publication ADM 76-338. Washington DC: U.S. Department of Health, Education and Welfare; 1976
10. Addington D, Addington J, Schissel BA: Calgary Depression Scale for Schizophrenia: Depression rating scale for schizophrenics. Schizophrenia Res 1990; 3:247-251
11. Folstein MF, Folstein SE, Hugh PR: Mini Mental State. A practical method for grading the cognitive state for the clinicians. J Psychiat Res 1975; 12:189-198
12. Chouinard G, Ross-Chounard A, Annable L, Jones BD: Extrapyramidal Symptoms Rating. Am J Neurol Sci 1980; 7:233
13. Blin O, Azorin JM, Bouhours P. Antipsychotic and anxiolytic properties of risperidone, haloperidol and methotrimeprazine in schizophrenic patients. J Clin Psychopharmacol 1996; 16(1):38-44
14. Kopala LC, Good KP, Honer WG. Extrapyramidal symptoms in first-episode schizophrenia: Response to low-dose risperidone. J Clin Psychopharmacol 1997; 17(4):308-313
15. Nair NP. Therapeutic equivalence of risperidone given once daily and twice daily in patients with schizophrenia. J Clin Psychopharmacol 1998; 18(2):103-110
16. Tollefson GD. Olanzapine: A new antipsychotic agent. J Clin Psychiatry Monograph 1997; 15(3):19-24
17. Madhusoodanan S, Suresh P, Brenner R, et al.: Experience with the atypical antipsychotics - risperidone and olanzapine in the elderly. Ann Clin Psychiatry 1999; II(3):113-118
18. Sajatovic M, Perez D, Brescan D, et al.: Olanzapine therapy in elderly patients with schizophrenia, psychopharmacol bull; in press.
19. Sweet RA, Pollack BG: New atypical anti psychotics: Experience and utility in the elderly, Drugs Aging 1998; 12:115-127
20. Satterlee WG, Reams SG, Burns PR, et al.: A clinical update on olanzapine treatment in schizophrenia and in elderly Alzheimer's disease patients, Psychopharmacol Bull 1995; 31:534
21. Moss AJ, Robinson JL: Long QT syndrome. Heart Disease Stroke 1992, 1:309
22. Bourne KF, Zipes DP, Heger JJ, et al.: The influence of autonomie nervous system on the QT interval in man. Am J Cardiol 1982, 50:1099
23. Moore NA: Behavioral pharmacology of olanzapine. J Clin Psychiatry Monograph 1997; 15(2):13-15